# A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

> **NCT02559570** · PHASE2 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 173 (actual)

## Conditions studied

- Functional Constipation in Children Ages 6-17 Years

## Interventions

- **DRUG:** Placebo
- **DRUG:** LIN Dose A
- **DRUG:** LIN Dose B
- **DRUG:** LIN Dose C
- **DRUG:** LIN 145 µg

## Key facts

- **NCT ID:** NCT02559570
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-03
- **Primary completion:** 2018-04-20
- **Final completion:** 2018-05-29
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2019-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02559570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02559570, "A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02559570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*